MyChesCo on MSN

Savara heads to JPMorgan conference as investors watch rare lung drug

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said members of its management team will present and hold one-on-one meetings at the 44th Annual J.P. Morgan Healthcare Conference, a closely watched ...

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with ...
The TimesDaily

A Caregiver’s Guide to Nebulizer Treatments for Seniors

Helping an older adult stay consistent with breathing treatments can feel like a full-time job - especially when COPD, asthma ...

Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
KTBS

Is a Nebulizer Right for Your Chronic Lung Disease?

(StatePoint) If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you receive can impact your health outcomes and quality of life. That ...
thedailytimes

Is a Nebulizer Right for Your Chronic Lung Disease?

Nov 15, 2025 Nov 15, 2025 Updated Nov 17, 2025 (StatePoint) If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you receive can impact ...